We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Biofortuna Expands its Immunoassay Development and Manufacturing Services
Product News

Biofortuna Expands its Immunoassay Development and Manufacturing Services

Biofortuna Expands its Immunoassay Development and Manufacturing Services
Product News

Biofortuna Expands its Immunoassay Development and Manufacturing Services


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Biofortuna Expands its Immunoassay Development and Manufacturing Services"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Biofortuna is expanding its IVD service portfolio to provide a greater focus on immunoassay design, development and manufacture. The company has made a significant investment in its production capabilities to include plate coating, washing, drying and quality control, creating an exceptional manufacturing suite for immunoassay kits. 


Biofortuna already has extensive experience in immunoassay development, and this expansion has been driven by the success of current customer projects and increasing demand from the market. These enhanced manufacturing capabilities will further strengthen the company’s existing immunoassay service and offer more flexibility to clients. 


This focus on immunoassay products will complement Biofortuna’s highly successful molecular IVD services, which include ISO 13485 accredited and FDA registered contract research, lyophilisation, air-drying, manufacturing, dispensing and kitting of diagnostic products.


Dr Simon Douglas, Biofortuna CEO, commented: “The success and growth of current projects has fueled the desire to increase our immunoassay offering. This expansion will allow for large scale manufacturing of ELISA-based kits to meet our customers’ growing needs.”


This article has been republished from materials provided by Biofotuna. Note: material may have been edited for length and content. For further information, please contact the cited source.
Advertisement